Critical Review: Nexalin Technology (NXL) and Its Peers

Nexalin Technology (NASDAQ:NXL) is one of 76 public companies in the “Electromedical equipment” industry, but how does it contrast to its peers? We will compare Nexalin Technology to related companies based on the strength of its risk, earnings, institutional ownership, dividends, valuation, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Nexalin Technology and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	0	0	0	0	N/A
Nexalin Technology Competitors	250	767	2030	101	2.63

As a group, “Electromedical equipment” companies have a potential upside of 25.27%. Given Nexalin Technology’s peers higher possible upside, analysts clearly believe Nexalin Technology has less favorable growth aspects than its peers.

Earnings & Valuation

This table compares Nexalin Technology and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nexalin Technology	$110,000.00	-$4.65 million	-1.58
Nexalin Technology Competitors	$987.79 million	$82.19 million	-7.71

Nexalin Technology’s peers have higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Nexalin Technology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,088.12%	-154.84%	-122.94%
Nexalin Technology Competitors	-152.14%	-47.46%	-5.34%

Risk & Volatility

Nexalin Technology has a beta of 5.17, meaning that its share price is 417% more volatile than the S&P 500. Comparatively, Nexalin Technology’s peers have a beta of 12.50, meaning that their average share price is 1,150% more volatile than the S&P 500.

Insider & Institutional Ownership

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 27.7% of Nexalin Technology shares are owned by insiders. Comparatively, 15.3% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Nexalin Technology peers beat Nexalin Technology on 8 of the 10 factors compared.

Nexalin Technology Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.